Tests MIL62 against placebo in adults with lupus
Tests the MIL62 antibody injection against a placebo in adults with lupus.
Plain-language title generated from the registry record
Registry title: A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07405970, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Mabworks Biotech Co., Ltd.
- Trial code
- NCT07405970
- Record updated
- 5 May 2026
- Original description
This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.Read full original descriptionShow less
A Phase 3 Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Systemic Lupus Erythematosus.
This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
Inclusion: Age 18-80 ; Diagnosis of systemic lupus erythematosus according to European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria ; Positive antinuclear antibodies (ANA) ≥ 1:80 at screening or positive anti- dsDNA ; High disease activity at screening ,SLEDAI-2000 score ≥8 (excluding alopecia score); On a stable dose of one or more standard treatments for SLE prior to the first administration；; Able and willing to provide written informed consent and to comply with the study protocol.
Exclusion: Received rituximab or any B-cell depleting drug within 9 months prior to the first dose; Received cyclophosphamide within 8 weeks prior to the first dose; received calcineurin inhibitors (cyclosporine, tacrolimus, etc., except for topical use) or plasma exchange therapy within 4 weeks prior to the first dose; Received a B-cell stimulating factor inhibitor such as Belimumab, and Telitacicept within 8 weeks prior to the first administration; TNF inhibitor, interleukin monoclonal antibody, JAK inhibitor, BTK inhibitor, TYK2 inhibitor, or thalidomide within 4 weeks prior to the first administration; Received live or attenuated vaccination within 28 days prior to the first administration; Participated in other clinical trials within 28 days prior to the first administration; Concomitant with other serious diseases; Positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with HBV DNA titer above the normal range; positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV); Subjects with known history of severe allergic reactions to humanized monoclonal antibodies MIL62; Other conditions unsuitable for participation in this study determined by the Investigator; Subjects with CD4+ T lymphocyte count < 200 cells/μL; Unsufficient organ function; Breastfeeding or pregnant women; Childbearing potential and unwillingness or impossibility to comply with a scientifically acceptable birth-control method.